Medivir AB (MVIRb.ST)
13 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|56||2016||Independent Chairman of the Board|
|43||2017||President, Chief Executive Officer|
|48||2015||Chief Financial Officer|
|52||Executive Vice President Strategic Regulatory Affairs and Market Access|
|42||2016||Chief Information Officer|
- BRIEF-Medivir announces new cancer project
- BRIEF-Medivir Q3 EBITDA loss widens
- BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA
- BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711
- BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C